Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 4/20 | 0.53 |
| ▸ | GHSR | Q92847 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 4/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051517 | 0.91 | GHSR (0.53) | DPP3GHSRTACR1BCHEF13A1 | |
| SCHEMBL29812309 | 0.88 | DPP3 (0.64) | DPP3GHSROPRM1TACR1 | |
| SCHEMBL30511908 | 0.88 | GHSR (0.56) | DPP3GHSROPRM1BCHEF13A1 | |
| SCHEMBL14906478 | 0.87 | DPP3 (0.49) | DPP3GHSROPRM1BCHE | |
| SCHEMBL14903326 | 0.87 | DPP3 (0.49) | DPP3GHSROPRM1TACR1 | |
| SCHEMBL14906600 | 0.87 | DPP3 (0.49) | DPP3GHSROPRM1BCHE | |
| SCHEMBL29878760 | 0.84 | ACE (0.56) | — | |
| SCHEMBL23380930 | 0.82 | GHSR (0.57) | DPP3GHSROPRM1 | |
| SCHEMBL30992101 | 0.80 | DPP3 (0.59) | DPP3GHSROPRM1TACR1 | |
| SCHEMBL2193319 | 0.79 | GHSR (0.52) | DPP3GHSROPRM1TACR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2019-03-26 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | DPP3 300/4885GHSR 451/4885OPRM1 1275/4885 |
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PNISR, APLNR, VIP | DPP3 300/4885GHSR 451/4885OPRM1 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.